$BAX · BAXTER INTERNATIONAL INC
Baxter International filed its Q3 2026 10-Q, reporting net income attributable to Baxter stockholders of $294M ($0.57 diluted EPS) on revenue of $2.976B, a 5.0% YoY increase. The quarter included a $253M gain on early debt extinguishment in other income. Operating cash flow from continuing operations reached $1.068B for the first nine months of 2026, nearly triple the $355M in the prior-year period, while long-term debt was reduced by $1.7B from year-end 2025.
- Q3 net income attributable to Baxter stockholders was $294M ($0.57 diluted EPS) vs. $(46)M loss in Q3 2025.
- Revenue rose 5.0% YoY to $2.976B; gross margin improved to 33.4% from 33.5% a year ago.
- Other income of $253M in Q3 2026 was driven by a gain on early extinguishment of debt.
- Long-term debt fell to $7.76B from $9.47B at year-end 2025; $600M in debt repaid during the nine months.
- Operating cash flow from continuing operations surged to $1.068B in 9M 2026 vs. $355M in 9M 2025.
BAX closed regular session at $23.50, down 7.70% on the day. Extended-hours last trade at $23.56 shows a modest +0.26% recovery vs. the regular close, suggesting the Q3 results are providing some stabilization after the sharp selloff.
Baxter's dramatic swing from loss to profit, aggressive debt reduction, and tripling of operating cash flow signal a post-Kidney Care separation turnaround gaining traction.
Baxter's 5% organic revenue growth and debt-reduction progress align with the med-tech sector's post-spin recovery playbook. The Kidney Care separation completed in 2025 continues to reshape comparables, with discontinued operations now a negligible drag.
The filing notes $365M in special items adversely impacting net income for the nine months ended September 30, 2026 ($0.71 per diluted share), indicating ongoing restructuring or one-time charges. Goodwill of $4.87B and intangible assets of $3.93B remain significant balance-sheet risks if impairment triggers emerge.